drugset / Trial / NCT03023878
Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
A phase 2, multicenter, open-label, single arm clinical trial in adults with newly diagnosed aggressive high-risk DLBCL.
Timeline
- Start
- 2017-03-13
- Primary completion
- 2019-04-04
- Completion
- 2019-10-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Blinatumomab | Monoclonal antibody | 112 ug | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Dexamethasone | Small molecule | 20 mg | Intravenous |
| Background | Doxorubicin | Other / unclassified | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Prednisone | Other / unclassified | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |
| Background | Vincristine | Small molecule | — | — |